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LETTER TO THE EDITOR Open Access
Predictors of clinical response to extrafine
and non-extrafine particle inhaled
corticosteroids in smokers and ex-smokers
with asthma
Fajri Gafar1,2, Ilse M. Boudewijn1,2*, Claire A. Cox1,2, Judith M. Vonk2,3, Siebrig Schokker4, Anne J. Lexmond5,
Henderik W. Frijlink5, Paul Hagedoorn5, Dirkje S. Postma1,2 and Maarten van den Berge1,2
Abstract
We performed a post-hoc analysis of the OLiVIA-study investigating whether current and ex-smoking asthmatics
with small airways dysfunction (SAD) show a better response in airway hyperresponsiveness (AHR) to small particle
adenosine after treatment with extrafine compared to non-extrafine particle inhaled corticosteroids (ICS), and to
investigate which clinical parameters predict a favorable response to both treatments. We show that smoking and
ex-smoking asthmatics with and without SAD have a similar treatment response with either extrafine or non-
extrafine particle ICS. We also found that lower blood neutrophils are associated with a smaller ICS-response in
smokers and ex-smokers with asthma, independent from the level of blood eosinophils.
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Asthma patients who smoke experience more severe
symptoms as well as airflow limitation, and benefit
less from treatment with inhaled corticosteroids
(ICS) compared with non-smoking asthmatics [1].
Additionally, smoking is associated with small
airways dysfunction (SAD) [2]. The small airways,
defined by a diameter ≤ 2 mm contribute to the re-
sistance in the airways of patients with obstructive
airways disease [3]. This has a clinical impact since
small airways can be inflamed in asthma and hence
narrowed [4]. We hypothesized that smokers and
ex-smokers with asthma would benefit more from
extrafine than non-extrafine particle ICS. However,
our OLiVIA-study showed that extrafine and
non-extrafine particle ICS were equally effective in
improving small airways function in current and
ex-smokers with asthma [5]. This outcome might be
ascribed to the fact that the presence of SAD was
not an inclusion criterion in our study. Therefore,
we performed a post-hoc analysis to investigate
whether current and ex-smoking asthmatics with
SAD show a better clinical response to extrafine
compared to non-extrafine particle ICS. Next, we in-
vestigated which clinical parameters, apart from the
presence of SAD, predict a favorable response to
extrafine and non-extrafine particle ICS.
The OLiVIA-study was an open-label, randomized,
three-way crossover, two-center study, comparing
two-week treatment with extrafine hydrofluoroalkane
(HFA)-beclomethasone 200 μg b.i.d. (QVAR) to
non-extrafine HFA-beclomethasone 400 μg b.i.d. (Cle-
nil) and non-extrafine HFA-fluticasone 250 μg b.i.d.
(Flixotide) [5]. The primary outcome was the change
in airway hyperresponsiveness (AHR) to small particle
adenosine, expressed as the provocative dose of ad-
enosine causing a 20% drop in FEV1 (forced expira-
tory volume at 1 s) from baseline to post-treatment
(ΔPD20). Small particle adenosine is a provocative
agent that acts indirectly via the release of mediators
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from inflammatory cells. It was chosen rather than
methacholine as it is a more sensitive measurement
to detect improvement in AHR after treatment with
ICS in patients with asthma [6].
Since there is no clearly defined golden standard for
SAD, we applied various parameters next to the PD20
adenosine, i.e. parameters of spirometry, body plethys-
mography, impulse oscillometry (IOS) and multiple
breath nitrogen washout (MBNW). We used cut-off
values for SAD parameters as follows: forced expiratory
flow between 25 and 75% of forced vital capacity [FEF25–
75] < lower limit of normal (LLN) from spirometry; ratio
of residual volume to total lung capacity [RV/TLC] >
upper limit of normal (ULN) from body plethysmogra-
phy; difference between resistance at 5 Hz and 20 Hz
[R5-R20] > 0.1 kPa sL
− 1 from IOS [7]; and ventilation het-
erogeneity of the acinar structures [Sacin] and conductive
airways [Scond] > ULN from MBNW [8]. These measure-
ments were taken at the baseline visit after an ICS wash-
out period of four to six weeks. The presence of SAD
was defined as: at least 3 out of 5 criteria fulfilled when
all lung function measurements were performed, or with
2 out of 3 criteria if MBNW was not carried out, which
was the case in 8 patients.
We performed a two-sided paired t-test or Wilcoxon
test to assess the difference in ΔPD20 adenosine after
treatment with extrafine compared to non-extrafine par-
ticle ICS in patients with SAD and patients without
SAD. PD20 values were log2-transformed prior to ana-
lyses. To investigate the difference in ΔPD20 between pa-
tients with SAD and without SAD within one treatment
group, we performed a student t-test or Mann-Whitney
test. Next, we explored which baseline variables (i.e.
demographics, small and large function measures, pres-
ence of atopy and blood leukocyte counts) were associ-
ated with ΔPD20 adenosine after extrafine and
non-extrafine particle ICS treatment using univariate lin-
ear regression analysis. We finally performed multivari-
ate linear regression analyses for each treatment type to
identify independent clinical predictors for ΔPD20 in-
cluding age, sex, smoking status, numbers of neutrophils
and eosinophils, and completed with those variables
showing a trend towards association with ΔPD20 (p <
0.1) in the univariate analysis. We allowed a maximum
Fig. 1 Change in PD20 adenosine from baseline to post-treatment with QVAR, Clenil and Flixotide in patients with and without small airways
dysfunction (SAD). Each line depicts a subject while the bold line depicts the mean change in PD20 adenosine in response to the treatment. PD20:
provocative dose of small particle adenosine causing a 20% drop in forced expiratory volume at 1 s (FEV1)
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of 7 variables to be included in the multivariate model.
The variables in this final model were selected based on
the following criteria: (1) the variable changed regression
coefficients (B) > 10%, (2) the model had highest total
explained variance (R2), and (3) the model preferably
included the highest number of subjects.
We analyzed 43 asthma patients (22 smokers and 21
ex-smokers), 42% being male, with mean (standard devi-
ation (SD)) age 45 (12.6) years, FEV1 83 (14.5) % pre-
dicted, and PD20 2.69 (3.41) mg. Baseline characteristics
of the study population are presented in Additional file
1: Table S1. At baseline, we found that SAD was present
in 18 (42%) patients (see Additional file 1: Table S2).
Asthma patients with and without SAD had similar re-
sponse in PD20 adenosine to extrafine (QVAR) and
non-extrafine particle ICS treatments (Clenil and Flixo-
tide) (Fig. 1; and Additional file 1: Table S3).
Results of the univariate linear regression analyses are
presented in Additional file 1: Table S4. Multivariate lin-
ear regression analyses (Table 1) showed that no param-
eters of SAD were associated with treatment response to
either small or large particle ICS. Lower numbers of
blood neutrophils were associated with a larger increase
in PD20 adenosine, independently from the level of
blood eosinophils, in patients treated with QVAR, Clenil
and Flixotide (all p < 0.05). Higher blood eosinophils
were also associated with a larger increase in PD20 ad-
enosine in patients treated with Flixotide (p < 0.05). Fi-
nally, younger age tended to be associated with a larger
increase in PD20 adenosine after using Clenil (p = 0.05).
We did not confirm our hypothesis that current
and ex-smoking asthmatics with SAD had a better
treatment response to QVAR compared to Clenil
and Flixotide. In line with previous reports on better
clinical effects of ICS in asthmatics with eosinophilia
[9–11], we show that higher blood eosinophils are
associated with a less severe AHR after treatment
with non-extrafine particle ICS (Flixotide). Of inter-
est, our study shows that higher blood neutrophils
are associated with more severe AHR after treatment
with both extrafine and non-extrafine particle ICS in
smokers and ex-smokers with asthma, independently
from the level of blood eosinophils. Findings by Tel-
enga et al. support that lower blood neutrophils are
associated with an increase in FEV1 after 2-week
ICS-therapy [11]. Taken together, we find that higher
blood neutrophils are associated with less clinical
ICS-response in smokers and ex-smokers with
Table 1 Multivariate linear regression analysis of baseline variables with change in airway hyperresponsiveness to small particle
adenosine (ΔPD20) as dependent variable in patients treated with QVAR, Clenil and Flixotide
Baseline predictors B 95% CI p-value R2
ΔPD20 QVAR Age, years −0.10 − 0.06; 0.04 0.703 0.64
Sex, male/ female 0.41 −0.78; 1.60 0.485
Current smoking, yes/no −0.47 −1.87; 0.93 0.493
Blood neutrophils, 109/L −0.55 −1.00; − 0.09 0.020
Blood eosinophils, 109/L 2.81 −0.48; 6.09 0.090
FEV1, % predicted 0.04 −0.01; 0.09 0.090
LCI at 2.5% −0.30 − 0.69; 0.08 0.117
ΔPD20 Clenil Age, years −0.06 − 0.12; 0.00 0.050 0.48
Sex, male/ female 0.80 −0.42; 2.03 0.192
Current smoking, yes/no −0.95 −2.33; 0.43 0.170
Blood neutrophils, 109/L −0.61 −1.04; − 0.18 0.006
Blood eosinophils, 109/L 3.04 −0.06; 6.15 0.054
FEV1, % predicted 0.03 −0.01; 0.07 0.180
ΔPD20 Flixotide Age, years −0.03 −0.08; 0.02 0.181 0.60
Sex, male/ female 0.85 −0.25; 1.96 0.125
Current smoking, yes/no −0.33 −1.51; 0.85 0.573
Blood neutrophils, 109/L −0.78 −1.13; −0.43 0.000
Blood eosinophils, 109/L 3.53 0.88; 6.17 0.011
FEV1, % predicted 0.002 −0.04; 0.04 0.937
RV/TLC, % predicted −0.03 −0.06; 0.004 0.089
B: regression coefficients; CI: Confidence Intervals; R2: total explained variance; ΔPD20: the change from baseline to post-treatment in the provocative dose of small
particle adenosine causing a 20% drop in FEV1; FEV1: forced expiratory volume in 1 s; LCI: lung clearance index; and RV/TLC: the ratio of residual volume to total
lung capacity
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asthma. However, our data (Additional file 1: Figure
S1) do not clearly show a cut-off value for eosino-
philia or neutrophilia that can be used in clinical
practice to define a positive response. Future studies
have to assess whether this change in inflammation
in peripheral blood is reflected by changes in the
small and larger airways.
A strength of the study is that we defined SAD by
cut-off levels applying multiple measurement tech-
niques including spirometry, body plethysmography,
impulse oscillometry and multiple breath nitrogen
washout. A limitation is the relatively small sample
size of patients with SAD and non-SAD which limits
the power of the study and raises the risk of type I
error. However, a post-hoc power analysis indicated
that we had a sufficient number of patients to detect
a difference of one doubling dose increase in PD20
adenosine between patients with and without SAD.
With a standard deviation of one doubling dose, β =
0.8 and α = 0.05, we would need 16 patients per
group while in our study, 18 patients with and 23
patients without SAD were investigated. Further
studies with larger sample sizes would provide a
clearer picture of SAD in smokers and ex-smokers
with asthma. Another possible limitation is that we
treated for two weeks which may have been too
short to improve SAD.
In conclusion, we show that smoking and
ex-smoking asthmatics with and without SAD have a
similar response to small particle adenosine after
treatment with either extrafine or non-extrafine par-
ticle ICS. These findings suggest that clinicians may
not need to consider SAD in order to decide whether
current- and ex-smoking asthmatics would benefit
preferentially from treatment with extrafine rather
than non-extrafine particle ICS. Of importance, we
find that lower blood neutrophils is a favorable pre-
dictor of ICS response, independent from the level of
blood eosinophils.
Additional file
Additional file 1: Table S1. Baseline characteristics. Table S2.
Baseline values of measurements of small airways dysfunction. Table
S3. Difference in ΔPD20 adenosine in patients with and without
small airways dysfunction after treatment with QVAR, Clenil and
Flixotide. Table S4. Univariate linear regression analysis of baseline
variables and change in airway hyperresponsiveness (ΔPD20) in
patients treated with QVAR, Clenil and Flixotide. Figure S1.
Scatterplots of significant correlations between baseline variables and
ΔPD20 adenosine. (PDF 731 kb)
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